By selecting the Yes option, leaving Amgen.eu option you understand that you are leaving the corporate page of Amgen Europe and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen is one of the world's leading biotechnology companies, present in more than 100 countries and with a global team of 23,000 employees.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
The rhythm of life unfolds at an ever-changing pace. Some moments pass in a blur. Others tick by in slow motion.
But no matter what the pace of life, nothing is more valuable than the time we have to experience it— and the chance we have to live each moment to its fullest.
That’s why Amgen operates at a different rhythm, moving quickly toward the future by combatting the world’s toughest diseases.
With roots in the biotech revolution, today Amgen is one of the world’s leading independent biotech companies.
With each decade, we stay on the cutting edge of medical discovery, inventing powerful therapies— and reliably delivering them to patients.
We fight the toughest diseases, such as cancer, heart disease, asthma, and osteoporosis to help millions of people globally.
We live in a new era of human health. And Amgen continues to accelerate the pace of change-- operating sustainably and drawing upon our deep knowledge of science to push beyond what’s known today.
We tap into a vast library of human and genetic data to unearth new insights into treating disease. We are creating new therapies that are more precise and personalized than ever before, advancing medicines that can work in new ways, such as targeting multiple pathways in the body at the same time.
Machine learning and artificial intelligence help us make medicines more quickly and effectively by helping to predict if they’ll be safe and effective.
We’re also removing barriers that limit equitable access to healthcare to make our medicines available to more patients around the world.
At Amgen, our mission is to serve patients because we want these rhythms of life to continue. We want you, and your loved ones, to make every moment count—and to count on having more moments
We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses such as cancer, cardiovascular disease, osteoporosis, asthma, rheumatoid arthritis and many others. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.
Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.
The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.
While bringing innovative medicines to people suffering from serious diseases is the best way Amgen can contribute to the greater good, we know that society confronts multiple challenges and we are working to do our part to address them. Our efforts fall into four categories:
To learn more, please visit www.amgen.com/responsibility.
*Valued at wholesale acquisition cost
